HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.04
+0.50 (+3.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close16.54
Open16.65
Bid15.17 x 1100
Ask19.68 x 3200
Day's Range16.45 - 17.05
52 Week Range13.24 - 21.48
Volume649,439
Avg. Volume720,678
Market Cap2.45B
Beta (3Y Monthly)1.74
PE Ratio (TTM)56.05
EPS (TTM)0.30
Earnings DateFeb 21, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.11
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications

    NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
    Zacks4 days ago

    Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for

    Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) CEO Pay Fair?
    Simply Wall St.6 days ago

    Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) CEO Pay Fair?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Helen Torley has been the CEO ofRead More...

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.

    Halozyme Therapeutics Inc NASDAQ/NGS:HALOView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HALO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HALO totaled $2.55 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call
    PR Newswire11 days ago

    Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call

    SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...

  • Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
    Zacks14 days ago

    Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

    Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

  • argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
    PR Newswire14 days ago

    argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology

    BREDA, the Netherlands and GHENT, Belgium and SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients. Under the terms of the agreement, argenx will pay an upfront payment of $30 million to Halozyme, $10 million per target for future target nominations and potential future payments of up to $160 million per selected target subject to achievement of specified development, regulatory and sales-based milestones.

  • Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
    Zacks17 days ago

    Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

    Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.

  • Business Wire18 days ago

    Halo Labs Provides Operational Update & Announces Closing of Promissory Note

    Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF) is pleased to provide an operational update given the recent developments at the Company in the past few months and announces the closing of a promissory note financing. Halo's CEO, Kiran Sidhu, stated: “As we start the new year off, I would like to provide our investors with an update on Halo as the end of 2018 was an incredibly busy time for the Company. In 2019, we expect to see the results of all that work come to fruition as the Company has transformed from a single state operator to a multi-state operator with California quickly become the driving force of the business.

  • Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
    Zacks20 days ago

    Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

    Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Alnylam Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...

  • Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
    PR Newswirelast month

    Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

    - Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation - Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with ...

  • Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) 19% Better Than Average?
    Simply Wall St.last month

    Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) 19% Better Than Average?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...

  • A Financial Overview of Vanda Pharmaceuticals in December
    Market Realist2 months ago

    A Financial Overview of Vanda Pharmaceuticals in December

    In the first nine months of 2018, Vanda Pharmaceuticals’ (VNDA) net revenues grew ~16% YoY to reach $140.1 million from $120.8 million. In the third quarter, the company’s net revenues amounted to $49.1 million, reflecting ~19% YoY growth. Wall Street analysts estimate that Vanda Pharmaceuticals will generate revenues of $191.7 million in fiscal 2018.

  • Vanda Pharmaceuticals: Recent Developments and Analyst Ratings
    Market Realist2 months ago

    Vanda Pharmaceuticals: Recent Developments and Analyst Ratings

    On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.

  • Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
    Zacks2 months ago

    Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure

    Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.

  • GlobeNewswire2 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Dec. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
    PR Newswire2 months ago

    Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

    SAN DIEGO , Dec. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 37th Annual ...

  • Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
    Zacks2 months ago

    Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder

    Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.

  • Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO)
    Insider Monkey2 months ago

    Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO)

    Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]

  • ACCESSWIRE2 months ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)

    NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") ...

  • GlobeNewswire3 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. – HALO

    Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. (“Halozyme” or the “Company”) (NASDAQ: HALO).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.